GLUE Sold Off on GFORCE-1 Because the Bar Had Already Moved Biomarkers improved, but Phase 1 data, rivals, and the ZEUS miss kept buyers on the sidelines. Credit: Monte Rosa Therapeutics Subscribe now Already have an account? Sign in.
